Drs Nicholas Silvestri and Gil Wolfe get right to the point about when and why thymectomy may be considered as an evidence-based option for treatment of myasthenia gravis.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/990461). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Long-term Effect of Thymectomy Plus Prednisone Versus Prednisone Alone in Patients With Non-thymomatous Myasthenia Gravis: 2-year Extension of the MGTX Randomised Trial https://pubmed.ncbi.nlm.nih.gov/30692052/

Randomized Trial of Thymectomy in Myasthenia Gravis https://pubmed.ncbi.nlm.nih.gov/27509100/

The Short and Long-term Effects of Open vs Minimally Invasive Thymectomy in Myasthenia Gravis Patients: A Systematic Review and Meta-analysis https://pubmed.ncbi.nlm.nih.gov/36539629/

Prognostic Factors for Conversion to Generalization in Ocular Myasthenia Gravis https://pubmed.ncbi.nlm.nih.gov/34106649/

Development of a Model Care Pathway for Myasthenia Gravis https://pubmed.ncbi.nlm.nih.gov/34770107/

Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update https://pubmed.ncbi.nlm.nih.gov/33917535/